Twist Bioscience (TWST) Set to Post Quarterly Earnings on Thursday

Twist Bioscience (NASDAQ:TWST) is expected to be posting its Q4 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.3845) per share and revenue of $123.55 million for the quarter. Parties can check the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Twist Bioscience Trading Up 12.0%

Shares of Twist Bioscience stock opened at $135.34 on Tuesday. Twist Bioscience has a 52-week low of $23.30 and a 52-week high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The company’s 50-day simple moving average is $151.23 and its 200-day simple moving average is $91.53. The firm has a market cap of $8.49 billion, a price-to-earnings ratio of -60.96 and a beta of 2.25.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Canaccord Genuity Group boosted their target price on Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. BWS Financial reiterated a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. UBS Group assumed coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Finally, Piper Sandler raised their price target on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Hold” and a consensus target price of $153.00.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 8,057 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,521,806.16. Following the completion of the transaction, the chief financial officer owned 100,576 shares in the company, valued at $18,996,794.88. This trade represents a 7.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the sale, the senior vice president owned 106,632 shares of the company’s stock, valued at $20,140,652.16. This trade represents a 8.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 495,279 shares of company stock valued at $80,489,387. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications.

The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Founded in 2013 and headquartered in South San Francisco, California, Twist serves customers in biotechnology, pharmaceutical, academic, agricultural and other industries around the world.